Recombinant IL13 (Tralokinumab Biosimilar) antibody

Catalog No. ABIN7487857

The Mammalian Cells Monoclonal anti-IL13 (Tralokinumab Biosimilar) antibody has been validated for ELISA. It is suitable to detect IL13 (Tralokinumab Biosimilar) in samples from Human.

Quick Overview for Recombinant IL13 (Tralokinumab Biosimilar) antibody (ABIN7487857)

Target: IL13 (Tralokinumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This IL13 (Tralokinumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-IL13 (Tralokinumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Tralokinumab Biosimilar - Anti-IL13 mAb

Characteristics: Antibody Type: IgG4-lambda

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG4 lambda

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for IL13 (Tralokinumab Biosimilar)

Target: IL13 (Tralokinumab Biosimilar)

Target Type: Biosimilar

Background: CAT-354
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.

CAS-No: 1044515-88-9